{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:06:16Z","timestamp":1783926376712,"version":"3.55.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013280","name":"Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","award":["22KJB350010"],"award-info":[{"award-number":["22KJB350010"]}],"id":[{"id":"10.13039\/501100013280","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373796"],"award-info":[{"award-number":["82373796"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574254"],"award-info":[{"award-number":["82574254"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273768"],"award-info":[{"award-number":["82273768"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.119010","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:17:27Z","timestamp":1780067847000},"page":"119010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development of highly selective, low-toxicity and orally available Mcl-1 inhibitors based on 3,5-dimethyl-4-sulfonimide-1H-pyrrole scaffold via P2\/P3 dual pocket binding optimization"],"prefix":"10.1016","volume":"316","author":[{"given":"Junjie","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengju","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziquan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabin","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qidong","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengchen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejmech.2026.119010_bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1478-3231.2006.01409.x","article-title":"Survival and apoptosis: a dysregulated balance in liver cancer","volume":"27","author":"Fabregat","year":"2007","journal-title":"Liver Int."},{"key":"10.1016\/j.ejmech.2026.119010_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113539","article-title":"Inhibitors of BCL2A1\/Bfl-1 protein: potential stock in cancer therapy","volume":"220","author":"Li","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119010_bib3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tcb.2012.08.011","article-title":"Delving deeper: MCL-1'S contributions to normal and cancer biology","volume":"23","author":"Perciavalle","year":"2013","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119010_bib4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pharmthera.2014.08.003","article-title":"Small molecule Mcl-1 inhibitors for the treatment of cancer","volume":"145","author":"Belmar","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119010_bib5","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119010_bib6","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/s41418-025-01454-2","article-title":"Deciphering molecular specificity in MCL-1\/BAK interaction and its implications for designing potent MCL-1 inhibitors","volume":"32","author":"Wei","year":"2025","journal-title":"Cell Death Differ."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119010_bib7","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/1078-0432.CCR-22-2088","article-title":"Mechanisms of MCL-1 protein stability induced by MCL-1 antagonists in B-Cell malignancies","volume":"29","author":"Tantawy","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119010_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41419-017-0035-2","article-title":"MCL-1 is a prognostic indicator and drug target in breast cancer","volume":"9","author":"Campbell","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2026.119010_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118079","article-title":"Recent advances of small-molecule Mcl-1 inhibitors or degraders as promising anti-cancer agents (2018-present)","volume":"299","author":"Chen","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119010_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108211","article-title":"MCL-1 as a potent target for cancer: recent advancements, structural insights and SAR studies","volume":"156","author":"Sharma","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119010_bib11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-020-01007-9","article-title":"MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents","volume":"13","author":"Bolomsky","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"14","key":"10.1016\/j.ejmech.2026.119010_bib12","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1080\/15384101.2022.2054096","article-title":"MCL-1 is a clinically targetable vulnerability in breast cancer","volume":"21","author":"Winder","year":"2022","journal-title":"Cell Cycle"},{"issue":"10","key":"10.1016\/j.ejmech.2026.119010_bib13","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/j.drudis.2020.07.021","article-title":"Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy","volume":"25","author":"Zhu","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119010_bib14","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1021\/acs.jmedchem.9b00983","article-title":"Hot-Spots of Mcl-1 protein","volume":"63","author":"Denis","year":"2020","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119010_bib15","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1021\/acs.jmedchem.3c01998","article-title":"Targeting myeloid Leukemia-1 in cancer therapy: advances and directions","volume":"67","author":"Deng","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119010_bib16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","article-title":"Targeting MCL-1 in cancer: current status and perspectives","volume":"14","author":"Wang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119010_bib17","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119010_bib18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/13543776.2023.2219394","article-title":"An updated patent review of Mcl-1 inhibitors (2020-2022)","volume":"33","author":"Liu","year":"2023","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.119010_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116270","article-title":"Targeting kelch-like (KLHL) proteins: achievements, challenges and perspectives","volume":"269","author":"Zhou","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119010_bib20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s43856-023-00380-z","article-title":"Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients","volume":"3","author":"Yuda","year":"2023","journal-title":"Commun. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119010_bib21","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat. Commun."},{"issue":"S3","key":"10.1016\/j.ejmech.2026.119010_bib22","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000969220.98838.e7","article-title":"P579: safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Azd5991 in Relapsed\/refractory hematologic malignancies: a phase 1 First-in-Human study","volume":"7","author":"Desai","year":"2023","journal-title":"HemaSphere"},{"issue":"Supplement 1","key":"10.1016\/j.ejmech.2026.119010_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-141417","article-title":"Co-Targeting MCL-1 and BCL-2 is highly synergistic in BH3 Mimetic- and Venetoclax\/Hypomethylating agent-resistant and TP53 mutated AML","volume":"136","author":"Carter","year":"2020","journal-title":"Blood"},{"issue":"7626","key":"10.1016\/j.ejmech.2026.119010_bib24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"issue":"401","key":"10.1016\/j.ejmech.2026.119010_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7049","article-title":"Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer","volume":"9","author":"Merino","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"22","key":"10.1016\/j.ejmech.2026.119010_bib26","doi-asserted-by":"crossref","first-page":"13762","DOI":"10.1021\/acs.jmedchem.0c01234","article-title":"Discovery of S64315, a potent and selective Mcl-1 inhibitor","volume":"63","author":"Szlavik","year":"2020","journal-title":"J. Med. Chem."},{"issue":"34","key":"10.1016\/j.ejmech.2026.119010_bib27","doi-asserted-by":"crossref","first-page":"22073","DOI":"10.1021\/acsomega.1c02595","article-title":"The effect of core replacement on S64315, a selective MCL-1 inhibitor, and its analogues","volume":"6","author":"Sipos","year":"2021","journal-title":"ACS Omega"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119010_bib28","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1021\/acs.jmedchem.5b01660","article-title":"Discovery of 2-Indole-acylsulfonamide Myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods","volume":"59","author":"Pelz","year":"2016","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.ejmech.2026.119010_bib29","doi-asserted-by":"crossref","first-page":"11330","DOI":"10.1021\/acs.jmedchem.1c00682","article-title":"Discovery of 3,5-Dimethyl-4-Sulfonyl-1H-Pyrrole-Based Myeloid cell leukemia 1 inhibitors with high affinity, selectivity, and oral bioavailability","volume":"64","author":"Zhu","year":"2021","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2026.119010_bib30","doi-asserted-by":"crossref","first-page":"9154","DOI":"10.1021\/acs.jmedchem.9b02047","article-title":"Discovery of a copper-based Mcl-1 inhibitor as an effective antitumor agent","volume":"63","author":"Lu","year":"2020","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2026.119010_bib31","doi-asserted-by":"crossref","first-page":"14370","DOI":"10.1021\/acs.jmedchem.4c01188","article-title":"Discovery of a Myeloid cell leukemia 1 (Mcl-1) inhibitor that demonstrates potent in vivo activities in mouse models of hematological and solid tumors","volume":"67","author":"Tarr","year":"2024","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2026.119010_bib32","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2426006122","article-title":"De novo discovery of a molecular glue-like macrocyclic peptide that induces MCL1 homodimerization","volume":"122","author":"Li","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119010_bib33","doi-asserted-by":"crossref","first-page":"8172","DOI":"10.1021\/acs.jmedchem.4c00277","article-title":"Histidine-covalent stapled alpha-helical peptides targeting hMcl-1","volume":"67","author":"Alboreggia","year":"2024","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119010_bib34","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1101\/gad.215871.113","article-title":"Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure","volume":"27","author":"Thomas","year":"2013","journal-title":"Genes Dev."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119010_bib35","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.stemcr.2018.01.005","article-title":"A non-apoptotic function of MCL-1 in promoting pluripotency and modulating mitochondrial dynamics in stem cells","volume":"10","author":"Rasmussen","year":"2018","journal-title":"Stem Cell Rep."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119010_bib36","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.molcel.2024.02.035","article-title":"Anti-apoptotic MCL-1 promotes long-chain fatty acid oxidation through interaction with ACSL1","volume":"84","author":"Wright","year":"2024","journal-title":"Mol Cell"},{"key":"10.1016\/j.ejmech.2026.119010_bib37","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.1038\/ncomms6637","article-title":"Beclin 1 restrains tumorigenesis through Mcl-1 destabilization in an autophagy-independent reciprocal manner","volume":"5","author":"Elgendy","year":"2014","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119010_bib38","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.trecan.2025.09.005","article-title":"Canonical and non-canonical intricacies of MCL-1 in cancer","volume":"11","author":"Mittal","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejmech.2026.119010_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113546","article-title":"NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes","volume":"154","author":"Daressy","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119010_bib40","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1021\/jm501258m","article-title":"Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity","volume":"58","author":"Bruncko","year":"2015","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119010_bib41","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1021\/acsmedchemlett.9b00625","article-title":"Chiral analogues of PFI-1 as BET inhibitors and their functional role in Myeloid malignancies","volume":"11","author":"Altenburg","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"19","key":"10.1016\/j.ejmech.2026.119010_bib42","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1002\/chem.201905461","article-title":"Increasing complexity: a practical synthetic approach to Three-dimensional, cyclic sulfoximines and first insights into their in vitro properties","volume":"26","author":"Boulard","year":"2020","journal-title":"Chemistry"},{"issue":"8","key":"10.1016\/j.ejmech.2026.119010_bib43","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1021\/jm1013693","article-title":"Synopsis of some recent tactical application of bioisosteres in drug design","volume":"54","author":"Meanwell","year":"2011","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2026.119010_bib44","doi-asserted-by":"crossref","first-page":"14243","DOI":"10.1021\/acs.jmedchem.0c00960","article-title":"Sulfoximines as rising stars in modern drug discovery? Current status and perspective on an Emerging functional group in medicinal chemistry","volume":"63","author":"Mader","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119010_bib45","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejmech.2016.09.091","article-title":"Sulfoximines from a medicinal chemist's perspective: physicochemical and in vitro parameters relevant for drug discovery","volume":"126","author":"Frings","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119010_bib46","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1021\/acs.jmedchem.5c00195","article-title":"Sulfilimines: an underexplored bioisostere for drug design?","volume":"68","author":"Arvidsson","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119010_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.141192","article-title":"Combined experimental and computational studies of N-Phenyl-o-benzenedisulfonimide: spectroscopy, DFT calculations, and Druggability analysis","volume":"1327","author":"Gumus","year":"2025","journal-title":"J. Mol. Struct."},{"issue":"15","key":"10.1016\/j.ejmech.2026.119010_bib48","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1002\/anie.201610456","article-title":"Sulfonimidamides in medicinal and agricultural chemistry","volume":"56","author":"Chinthakindi","year":"2017","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119010_bib49","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/ijc.25484","article-title":"A novel BH3 mimetic S1 potently induces Bax\/bak-dependent apoptosis by targeting both Bcl-2 and Mcl-1","volume":"128","author":"Zhang","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.ejmech.2026.119010_bib50","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1021\/jm101181u","article-title":"3-Thiomorpholin-8-oxo-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile (S1) based molecules as potent, dual inhibitors of B-cell lymphoma 2 (Bcl-2) and myeloid cell leukemia sequence 1 (Mcl-1): structure-based design and structure-activity relationship studies","volume":"54","author":"Zhang","year":"2011","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119010_bib51","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1021\/acs.jmedchem.8b01991","article-title":"Discovery of potent myeloid cell Leukemia-1 (Mcl-1) inhibitors that demonstrate in vivo activity in mouse xenograft models of human cancer","volume":"62","author":"Lee","year":"2019","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119010_bib52","doi-asserted-by":"crossref","first-page":"6178","DOI":"10.1016\/j.apsb.2025.10.004","article-title":"m(6)A readers: promising therapeutic targets in cancer treatment","volume":"15","author":"Wang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"8","key":"10.1016\/j.ejmech.2026.119010_bib53","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1158\/1535-7163.MCT-14-0928","article-title":"MCL-1 is a key determinant of breast cancer cell survival: validation of MCL-1 dependency utilizing a highly selective small molecule inhibitor","volume":"14","author":"Xiao","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"issue":"37","key":"10.1016\/j.ejmech.2026.119010_bib54","doi-asserted-by":"crossref","first-page":"17248","DOI":"10.1039\/D5SC04324G","article-title":"Discovery of an allosteric 14-3-3 inhibitor for suppressing NRF2-driven cancer via phenotypic screening and chemoproteomic-based target deconvolution","volume":"16","author":"Zhao","year":"2025","journal-title":"Chem. Sci."},{"issue":"22","key":"10.1016\/j.ejmech.2026.119010_bib55","doi-asserted-by":"crossref","first-page":"10258","DOI":"10.1021\/acs.jmedchem.9b01310","article-title":"Discovery and in vivo evaluation of macrocyclic Mcl-1 inhibitors featuring an alpha-hydroxy phenylacetic acid pharmacophore or bioisostere","volume":"62","author":"Rescourio","year":"2019","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.ejmech.2026.119010_bib56","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1021\/acs.jmedchem.9b00134","article-title":"Structure-guided discovery of a selective Mcl-1 inhibitor with cellular activity","volume":"62","author":"Szlavik","year":"2019","journal-title":"J. Med. Chem."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2026.119010_bib57","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.canlet.2014.03.017","article-title":"Imperatorin induces Mcl-1 degradation to cooperatively trigger Bax translocation and Bak activation to suppress drug-resistant human hepatoma","volume":"348","author":"Li","year":"2014","journal-title":"Cancer Lett."},{"issue":"14","key":"10.1016\/j.ejmech.2026.119010_bib58","doi-asserted-by":"crossref","first-page":"14945","DOI":"10.1021\/acs.jmedchem.5c00987","article-title":"Discovery of 2-Pyrazolylpyrimidinone derivatives as new SPOP inhibitors for renal cell carcinoma therapy","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2026.119010_bib59","doi-asserted-by":"crossref","first-page":"18670","DOI":"10.1021\/acs.jmedchem.5c01820","article-title":"Discovery of phosphorylated peptidomimetics targeting Cbl-b SH2 domain as orthosteric Cbl-b inhibitors by an optimized fluorescence polarization competition assay","volume":"68","author":"Li","year":"2025","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119010_bib60","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.chembiol.2023.12.005","article-title":"Bivalent inhibitors of the BTB E3 ligase KEAP1 enable instant NRF2 activation to suppress acute inflammatory response","volume":"31","author":"Lu","year":"2024","journal-title":"Cell Chem. Biol."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119010_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/molecules31040753","article-title":"Scaffold hopping-guided design of novel PIM-1 inhibitors with anticancer activities","volume":"31","author":"Xin","year":"2026","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119010_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117384","article-title":"Discovery of beta-amino acid substituted naphthalene sulfonamide derivatives as potent Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 (Keap1-Nrf2) protein-protein interaction inhibitors for ulcerative colitis management","volume":"288","author":"Zhao","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"33","key":"10.1016\/j.ejmech.2026.119010_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202506618","article-title":"Supramolecular host-guest assemblies for tunable and modular lysosome-targeting protein degradation","volume":"64","author":"Chen","year":"2025","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2026.119010_bib64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.freeradbiomed.2025.02.042","article-title":"A Keap1-recruiting BRD4 degrader offers a single-molecular polypharmacology approach for the treatment of metabolic dysfunction-associated steatohepatitis","volume":"232","author":"Zhang","year":"2025","journal-title":"Free Radic. Biol. Med."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119010_bib65","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.1021\/acs.jmedchem.4c03069","article-title":"Multi-water bridges enable design of BET BD1-Selective inhibitors for pancreatic cancer therapy","volume":"68","author":"Chen","year":"2025","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119010_bib66","doi-asserted-by":"crossref","first-page":"11062","DOI":"10.1021\/acs.jmedchem.5c00040","article-title":"Rational design of novel Quinazolinone-pyrrolodihydropyrrolone analogs as PIM\/HDAC dual-target inhibitors for the treatment of acute myelocytic leukemia","volume":"68","author":"Xin","year":"2025","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.ejmech.2026.119010_bib67","doi-asserted-by":"crossref","first-page":"12521","DOI":"10.1021\/acs.jmedchem.4c00403","article-title":"Discovery of a NCOA4 degrader for labile iron-dependent ferroptosis inhibition","volume":"67","author":"Ji","year":"2024","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119010_bib68","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1021\/acs.jmedchem.4c02616","article-title":"Discovery of selenium-containing derivatives as potent and orally bioavailable GLP-1R agonists","volume":"68","author":"Chen","year":"2025","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119010_bib69","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1021\/acs.jmedchem.4c01720","article-title":"Discovery of WDR5\u2013MLL1 and HDAC dual-target inhibitors for the treatment of acute myeloid leukemia","volume":"68","author":"Long","year":"2025","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:19:43Z","timestamp":1783923583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426004551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":69,"alternative-id":["S0223523426004551"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119010","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of highly selective, low-toxicity and orally available Mcl-1 inhibitors based on 3,5-dimethyl-4-sulfonimide-1H-pyrrole scaffold via P2\/P3 dual pocket binding optimization","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119010"}}